24 companies · median 19 of 36 checks · prices as of 2026-10-23
Pharma and chemical stocks.
Sorted by how many checks each one passes. Sort by any column to see who is cheapest, who is growing, or who has the strongest balance sheet - and how that compares with what is normal for the industry.
Ranked by checks passed
24 companies in this sector→The pharmaceutical and chemical companies we cover are not one trade: Eli Lilly (LLY) passes 27 of its 36 checks and Viking Therapeutics (VKTX) passes 4, with a median of 19.
→LLY, JNJ, ABBV carry 54% of the $4.31T we cover here.
| Save | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
 Eli LillyLLYMakes drugs for diabetes, obesity and cancer, led by the GLP-1 medicines Mounjaro and Zepbound.Report | -2.5% | +57.7% | 0 | 6 | 6 | 4 | 5 | 6 | 27/36 | |
 Bristol Myers SquibbBMYMakes cancer and blood-thinning drugs, working through patent expiries on its biggest sellers.Report | -2.4% | +44.7% | 5 | 3 | 6 | 4 | 5 | 2 | 25/36 | |
 Regeneron PharmaceuticalsREGNMakes Eylea for eye disease and Dupixent for allergic conditions.Report | -1.7% | +38.4% | 3 | 2 | 6 | 6 | 4 | 4 | 25/36 | |
 AbbVieABBVMakes Humira, Skyrizi and Rinvoq for immune diseases, plus Botox and cancer drugs.Report | +0.2% | +28.6% | 1 | 3 | 5 | 3 | 6 | 6 | 24/36 | |
 Procter & GamblePGSells household brands from Tide and Pampers to Gillette and Olay.Report | -2.8% | +8.9% | 1 | 2 | 5 | 5 | 6 | 5 | 24/36 | |
 AmgenAMGNMakes biologic drugs for cancer, bone and heart disease, and is entering obesity.Report | -1.8% | +52.5% | 1 | 2 | 6 | 3 | 5 | 6 | 23/36 | |
 Abbott LaboratoriesABTMakes medical devices, diagnostics, nutrition products and generic drugs.Report | +1.2% | -16.9% | 3 | 2 | 5 | 4 | 6 | 3 | 23/36 | |
 Johnson & JohnsonJNJMakes prescription drugs and medical devices, after spinning off its consumer brands.Report | -1.4% | +39.8% | 1 | 2 | 6 | 4 | 5 | 2 | 20/36 | |
 Vertex PharmaceuticalsVRTXMakes the only approved medicines for cystic fibrosis, and is expanding into pain and kidney disease.Report | -2.1% | +22.9% | 0 | 2 | 6 | 4 | 5 | 3 | 20/36 | |
 MerckMRKMakes Keytruda, the world's best-selling cancer drug, plus vaccines and animal health products.Report | -1.3% | +70.7% | 1 | 2 | 4 | 2 | 6 | 4 | 19/36 | |
 Gilead SciencesGILDMakes HIV and hepatitis drugs, and is building a cancer business.Report | -0.7% | +31.6% | 1 | 3 | 2 | 2 | 5 | 6 | 19/36 | |
 PfizerPFEMakes vaccines and prescription drugs, working through the fall in Covid revenue.Report | -1.3% | +30.0% | 1 | 1 | 4 | 3 | 4 | 6 | 19/36 | |
 e.l.f. BeautyELFSells low-priced color cosmetics and skincare, growing fast with younger shoppers.Report | -0.7% | -7.6% | 2 | 3 | 3 | 4 | 2 | 5 | 19/36 | |
 Sarepta TherapeuticsSRPTMakes treatments for Duchenne muscular dystrophy, including the gene therapy Elevidys.Report | -2.5% | -21.1% | 4 | 2 | 1 | 4 | 1 | 0 | 12/36 | |
 ModernaMRNAMakes mRNA vaccines, still living off the Covid franchise while it develops new ones.Report | -1.3% | +645.3% | 0 | 1 | 0 | 4 | 1 | 5 | 11/36 | |
 AbCellera BiologicsABCLDiscovers antibodies for drugmakers, and is now developing its own drug candidates.Report | +4.0% | +116.1% | 0 | 2 | 0 | 4 | 1 | 3 | 10/36 | |
 Tilray BrandsTLRYSells cannabis in Canada and abroad, and craft beer and spirits in the US.Report | -4.1% | -80.6% | 4 | 2 | 0 | 2 | 1 | 0 | 9/36 | |
 ImmunityBioIBRXSells Anktiva, an immunotherapy for bladder cancer, and develops other cancer treatments.Report | -1.1% | +248.3% | 1 | 3 | 0 | 1 | 0 | 3 | 8/36 | |
 Beam TherapeuticsBEAMDeveloping base-editing medicines that rewrite single letters of DNA, still in clinical trials.Report | -2.1% | -13.1% | 1 | 4 | 0 | 3 | 0 | 0 | 8/36 | |
 Recursion PharmaceuticalsRXRXUses machine learning and automated labs to discover drugs, still in clinical trials.Report | +3.4% | -35.7% | 1 | 1 | 0 | 2 | 0 | 3 | 7/36 | |
 NovavaxNVAXMakes protein-based vaccines, with its Covid vaccine now sold through Sanofi.Report | -2.9% | +14.7% | 2 | 0 | 1 | 2 | 0 | 2 | 7/36 | |
 Intellia TherapeuticsNTLADeveloping CRISPR medicines that edit genes inside the body, still in clinical trials.Report | +0.4% | -54.4% | 1 | 1 | 1 | 4 | 0 | 0 | 7/36 | |
 CRISPR TherapeuticsCRSPDevelops CRISPR gene-editing medicines, with an approved sickle cell treatment sold with Vertex.Report | -1.2% | -25.8% | 0 | 2 | 0 | 3 | 0 | 0 | 5/36 | |
 Viking TherapeuticsVKTXDeveloping obesity drugs, both a weight-loss injection and a pill, pre-revenue.Report | -5.5% | -22.3% | 0 | 0 | 0 | 4 | 0 | 0 | 4/36 |
The filings behind this table close between 2026-06-28 and 2026-09-30, because these companies do not share a fiscal calendar; prices are the close of 2026-10-23. Each name links to its full report; every score is a count of pass-or-fail checks read from that company's own filings.
Where the sector falls short
median score per axis→Value is where the pharmaceutical and chemical companies we cover come up short most often, at a median of 1 of 6, while Financial health runs at 4.
| Value | ●○○○○○ | 1 of 6 |
| Growth | ●●○○○○ | 2 of 6 |
| Quality | ●●●○○○ | 3 of 6 |
| Financial health | ●●●●○○ | 4 of 6 |
| Shareholder returns | ●●●○○○ | 3 of 6 |
| Trend | ●●●○○○ | 3 of 6 |
What a normal margin looks like here
sector percentiles · 113 filers→Gross margin varies widely among pharmaceutical and chemical companies: the middle of the field runs from 28% to 58%, with a midpoint of 42% measured over 113 filers.
| Metric | Bottom third | Midpoint | Top third |
|---|---|---|---|
| Gross margin n=113 | 27.7% | 41.6% | 58.1% |
| Operating margin n=252 | -31.8% | -2.3% | 10.5% |
| Net margin n=271 | -21.5% | -2.0% | 8.2% |
| Return on equity n=249 | -27.2% | -5.6% | 8.8% |
Who grows, and who keeps it
every company in the industry→ABBV, ABT, AMGN, GILD, REGN, VRTX do both: growing faster than this industry's middle and keeping more of each sale than it does. The industry's middle is 0% growth on a 8% margin. MRNA does neither.
A year of price
not a fact about the business→15 of 24 are up over twelve months and the median move is +25.8% - Moderna (MRNA) at +645.3% against Tilray Brands (TLRY) at -80.6%. Price is not a fact about a business, and the Trend chapter of each report says what it is measured on.
Head to head
3 pairsThe table above gives the order. These put two of them in one column each, so you can see where the difference actually is.